New Drugs
| Brand/Generic | Company | Description |
|---|---|---|
|
Calquence acalabrutinib |
AstraZeneca | An oral tyrosine kinase inhibitor for mantle cell lymphoma. |
|
Demylocan decitabine |
Pendopharm | IV pyrimidine analogue for treatment of myelodysplastic syndromes. |
|
Emgality galcanezumab |
Lilly | A calcitonin-gene related peptide receptor antagonist to prevent migraine. |
|
Esperoct turoctocog alfa pegol |
Novo Nordisk | A recombinant PEGylated antihemophilic Factor VIII for prophylaxis and treatment in patients with hemophilia A. |
|
Evenity romosozumab |
Amgen | A sclerostin inhibitor for treatment of postmenopausal osteoporosis in women at high risk for fracture. |
|
Idhifa enasidenib |
Celgene | An agent for relapsed/refractory acute myeloid leukemia with IDH2 mutation. |
|
Influvac Tetra influenza vaccine |
BGP Pharma/Mylan | New quadrivalent formulation flu vaccine for adults. |
|
Lokelma sodium zirconium cyclosilicate |
AstraZeneca | A potassium binder for hyperkalemia. |
|
Lorbrena lorlatinib |
Pfizer | An oral kinase inhibitor for ALK-positive metastatic non-small cell lung cancer. |
|
Lutathera lutetium (177Lu) oxodotreotide |
Advanced Accelerator Apps. | IV radiopharmaceutical for gastroenteropancreatic neuroendocrine tumors. |
|
Nerlynx neratinib |
Puma (U.S.)/Knight Therapeutics | An oral protein kinase inhibitor for early stage breast cancer. |
|
Ogivri trastuzumab |
BGP Pharma/Mylan | First biosimilar to Herceptin. |
|
Onpattro patisiran |
Alnylam Netherlands | An injectable agent for polyneuropathy of hereditary transthyretin-mediated amyloidosis. |
|
Onstryv safinamide |
Valeo | An MAO-B inhibitor add-on therapy for "off" Parkinson's episodes in patients on stable doses of levodopa. |
|
Oxervate cenegermin |
Dompé (Italy) | An ophthalmic recombinant human nerve growth factor for moderate or severe neurotrophic keratitis. |
|
Skyrizi risankizumab |
AbbVie | A monoclonal antibody for moderate to severe plaque psoriasis. |
|
Tibella tibolone |
BioSyent | Oral synthetic steroid hormone prodrug for vasomotor symptoms in postmenopausal women. |
|
Trazimera trastizumab |
Pfizer | New biosimilar to Herceptin. |
|
Truxima rituximab |
Celltrion/Teva | A monoclonal antibody for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. |
|
Ultomiris ravulizumab |
Alexion | A monoclonal antibody for paroxysmal nocturnal hemoglobinuria. |
|
Verzenio abemaciclib |
Lilly | Oral protein kinase inhibitor for advanced or metastatic breast cancer. |
|
Vitrakvi larotrectinib |
Bayer | An oral kinase inhibitor for treating solid tumours. |
|
Vizimpro dacomitinib |
Pfizer | Oral pan-human epidermal growth factor receptor inhibitor for advanced/metastatic non-small cell lung cancer. |
|
Vonvendi von Willebrand factor, recombinant (vonicog alfa) |
Shire | IV rVWF for treatment/control of bleeding episodes in von Willebrand disease. |
|
Yescarta axicabtagene ciloleucel |
Gilead Sciences | A CD19-directed genetically modified autologous T cell immunotherapy for relapsed/refractory large B cell lymphoma. |
|
Zejula niraparib |
GSK | A PARP enzyme inhibitor for recurrent ovarian cancer. |
|
Zirabev bevacizumab |
Pfizer | A biosimilar to Avastin. |
| Brand/Generic | Company | Description |
|---|---|---|
|
Baqsimi glucagon |
Lilly | New intranasal formulation for severe hypoglycemia. |
|
Combogesic acetaminophen/ibuprofen |
Aft Pharma. | A fixed-dose combination formulation for acute pain or fever reduction in adults. |
|
Cystadrops cysteamine HCl |
Recordati Rare Diseases Canada | An ophthalmic cystine-depleting agent for corneal cystine crystal deposits in patients with cystinosis. |
|
Dovato lamivudine/dolutegravir |
ViiV Healthcare | A new combination formulation for HIV-1 infection. |
|
Envarsus PA tacrolimus |
Endo/Paladin Labs | A prolonged-release tablet formulation for prophylaxis of kidney or liver transplant rejection. |
|
Ivozfo fosfomycin |
Verity Pharm. | New IV formulation antibiotic for infections in adults, children, and neonates. |
|
Renvela sevelamer |
Sanofi-Aventis | New oral suspension formulation for hyperphosphatemia in children. |
|
Tolak fluorouracil |
Hill Dermaceuticals | New 4% topical cream formulation for actinic keratosis lesions of the face, ears, and scalp. |
|
Tremfya One-Press guselkumab |
Janssen | New single-dose auto-injector product. |
| Brand/Generic | Company | Description |
|---|